The PennZone

  • Home
  • Business
  • Health
  • Technology
  • Non-profit
  • Financial
  • Services
  • Entertainment
  • Construction

$280B Invested, Mental Health Worsens—CCHR Demands Audit and Accountability
The PennZone/10288888

Trending...
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
CCHR Demands Audit and Accountability
Expert declares mental health and psychiatry are in a tailspin. CCHR warns of psychiatric treatment risks, rising drug deaths, and poor psychiatric hospital outcomes requiring close scrutiny.

LOS ANGELES - PennZone -- Citizens Commission on Human Rights International, a leading mental health industry watchdog, is calling for a federal audit of the $280 billion spent annually on mental health services, citing decades of failed outcomes and lack of meaningful improvements. Additionally, as CCHR has been exposing since the 1990s, millions of dollars have been wasted on National Institute of Mental Health (NIMH)-funded behavioral and psychiatric research that has included studying whiptail lizards, insects, electric fish and $3.1 million spent on the "vocal learning" of birds. Despite this massive investment, mental health in the U.S. continues to decline. CCHR warns that billions are being squandered on treatment-caused harm, overlooked polypharmacy risks, and rising deaths linked to psychotropic drugs.

President of CCHR, Jan Eastgate, said, "One thing we cannot be thankful for this year is an improved mental health system. We must acknowledge the financial costs and the toll on patients' health caused by extremely poor therapy outcomes, lack of cures, and rising deaths. The industry is plagued by iatrogenesis—the phenomenon of the 'healer' causing harm."

According to TIME magazine, "The U.S. has reached peak therapy. Counseling has become fodder for hit books, podcasts, and movies. Professional athletes, celebrities, and politicians routinely go public with their mental health struggles….  But something isn't adding up. Even as more people flock to therapy, U.S. mental health is getting worse by multiple metrics. Suicide rates have risen by about 30% since 2000."[1]

More on The PennZone
  • AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
  • Inkdnylon Expands National Uniform Embroidery Services
  • Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
  • Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
  • Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer

Polypharmacy, the practice of prescribing multiple psychotropic drugs simultaneously, is alarmingly common. This approach often leads to harmful drug interactions. Among the most overprescribed drugs and dangerous drugs are benzodiazepines, commonly referred to as "benzos." From mid-February to mid-March of 2020, prescriptions for these increased by 34%. Within a few short weeks, patients can develop a physical dependence on them ending up worse off than before the medications, struggling with addiction and withdrawal. Benzos can also have serious side effects, including respiratory depression, which can cause death. Stanford psychiatrist Anna Lembke, lead author of a New England Journal of Medicine essay, calls our overprescribing and overuse of benzos a "hidden epidemic."[2]

Over 21 years (1999-2019), 51,446 psychotropic-drug-implicated deaths (where psychotropic drugs were a contributing cause of death) occurred, with the annual psychotropic-drug-implicated death rate increasing over 3.4 times from 0.40 to 1.37 per 100,000. During the same period, there were also 649,697 psychotropic drug overdoses.[3]

In psychiatry, iatrogenesis has traditionally been linked to complications of psychotropic drug treatment, Medical Xpress reports. "Current classification systems in psychiatry fail to consider the iatrogenic components of psychopathology related to behavioral toxicity [the negative effects of therapeutic levels of medication]." These drugs' "paradoxical effects, manifestations of tolerance (loss of clinical effect, refractoriness), withdrawal and post-withdrawal disorders, are increasingly common due to the widespread use of psychotropic drugs in the general population."[4] In other words, psychiatry often ignores the harmful side effects caused by psychiatric drugs, such as worsening mental health and withdrawal symptoms, which are becoming more common as these drugs are widely used.

There are at least 180 psychiatric drugs on the market, not including all generic versions. Some of the iatrogenic effects include irreversible movement disorders causing uncontrollable muscle contractions such as tardive dyskinesia (TD), akathisia and dystonia. TD occurs in 20%-50% of patients taking antipsychotics and is also linked to antidepressants, mood stabilizers and stimulants.[5]

More on The PennZone
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
  • KIKO NATION TOKEN (Official Release)
  • Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology

Some psychotropics are nearly six times more likely to drive the person taking them to suicide than those not taking them, while spending time in a psychiatric hospital can increase that risk of self-inflicted death by 44 times.[6]

Clinical Psychology Science and Practice reported there is considerable evidence of heightened suicide risk and other negative outcomes during and immediately following hospitalization. As such, psychiatric hospitalization is iatrogenic. Despite limited research demonstrating its effectiveness in reducing suicide risk, inpatient hospitalization remains a primary "treatment" (often legally mandated, or forced) for individuals with high risk of suicide.[7]

Stanton Peele, Ph.D., states that "The world of mental health and psychiatry is in a tailspin," and cites Insel's "own confessional professional memoir," admitting, "The U.S., a country that leads the world in spending on medical research, also stands out for its dismal outcomes in people with mental illnesses. Indeed, over the last three decades, even as the government invested billions of dollars in better understanding the brain, by some measures, those outcomes have deteriorated."[8]

Founded in 1969 by the Church of Scientology and renowned University of New York psychiatrist Prof. Thomas Szasz, CCHR is calling for a transparent audit of the funds allocated to psychiatric services and their outcomes, and mental health research under NIMH. This audit aims to identify the failed treatments and programs that have contributed to the worsening state of the nation's mental health system.

Sources:

[1] time.com/6308096/therapy-mental-health-worse-us/

[2] time.com/6280929/polypharmacy-dangers-essay/

[3] pmc.ncbi.nlm.nih.gov/articles/PMC8355085/

[4] medicalxpress.com/news/2019-07-iatrogenic-disorders-psychiatry-common-neglected.html

[5] www.ncbi.nlm.nih.gov/pmc/articles/PMC5472076/

[6] link.springer.com/article/10.1007/s00127-014-0912-2

[7] www.researchgate.net/publication/339741738_The_potential_iatrogenic_effects_of_psychiatric_hospitalization_for_suicidal_behavior_A_critical_review_and_recommendations_for_research

[8] peele.net/lib/americanpsychiatry.html

Contact
CCHR International
***@cchr.org


Source: Citizens Commission on Human Rights
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • African American Genealogy Group Launches 2025 Raffle Fundraiser to Support Legacy Research
  • Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
  • Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
  • LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
  • Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
  • Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
  • Ring in the Season with Free Holiday Jazz from The Jazz Sanctuary
  • America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
  • "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
  • Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 484
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 191
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 102
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • BITE Data raises $3m to build AI tools for global trade compliance teams
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress

Similar on PennZone

  • Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us